Psyence Biomedical Ltd. (PBM)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Psyence Biomedical Ltd.
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Quarterly Financials
| Metric | 2024-09-30 | 2025-09-30 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Operating Income | (1.2M) | (1.5M) |
| Net Income | 141K | (753K) |
| Diluted EPS | $25.44 | $-3.19 |
Annual Financials
| Metric | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (3.2M) | (44.2M) | (3.7M) | (6.2M) |
| Net Income | (3.2M) | (51.2M) | 1.0M | (6.9M) |
| Diluted EPS | $-940.02 | $-14,274.29 | $261.02 | N/A |